Study Sheds Light on the Causes of Cerebral Palsy
News Aug 05, 2015
Cerebral palsy (CP) is the most common cause of physical disability in children. Every year 140 children are diagnosed with cerebral palsy in Quebec.
It has historically been considered to be caused by factors such as birth asphyxia, stroke and infections in the developing brain of babies. In a new game-changing Canadian study, a research team from The Hospital for Sick Children (SickKids) and the Research Institute of the McGill University Health Centre (RI-MUHC) has uncovered strong evidence for genetic causes of cerebral palsy that turns experts’ understanding of the condition on its head.
The study could have major implications on the future of counselling, prevention and treatment of children with cerebral palsy.
“Our research suggests that there is a much stronger genetic component to cerebral palsy than previously suspected,” says the lead study author Dr. Maryam Oskoui, Paediatric neurologist at The Montreal Children’s Hospital (MCH) of the MUHC, co-director of the Canadian Cerebral Palsy Registry and an Assistant Professor in the Department of Paediatrics and Department of Neurology and Neurosurgery at McGill University. “How these genetic factors interplay with other established risk factors remains to be fully understood. For example, two newborns exposed to the same environmental stressors will often have very different outcomes. Our research suggests that our genes impart resilience, or conversely a susceptibility to injury.”
Children with cerebral palsy have difficulties in their motor development early on, and often have epilepsy and learning, speech, hearing and visual impairments. Two out of every thousand births are affected by cerebral palsy with a very diverse profile; some children are mildly affected while others are unable to walk on their own or communicate. Genetic testing is not routinely done or recommended, and genetic causes are searched for only in rare occasions when other causes cannot be found.
The research team performed genetic testing on 115 children with cerebral palsy and their parents from the Canadian Cerebral Palsy Registry, many of which had other identified risk factors. They found that 10 per cent of these children have copy number variations (CNVs) affecting genes deemed clinically relevant. In the general population such CNVs are found in less than one per cent of people. CNVs are structural alterations to the DNA of a genome that can be present as deletions, additions, or as reorganized parts of the gene that can result in disease.
“When I showed the results to our clinical geneticists, initially they were floored,” says Dr. Stephen Scherer, Principal Investigator of the study and Director of The Centre for Applied Genomics (TCAG) at SickKids. “In light of the findings, we suggest that genomic analyses be integrated into the standard of practice for diagnostic assessment of cerebral palsy.”
The study also demonstrates that there are many different genes involved in cerebral palsy. “It’s a lot like autism, in that many different CNVs affecting different genes are involved which could possibly explain why the clinical presentations of both these conditions are so diverse,” says Scherer, who is also Director of the University of Toronto McLaughlin Centre. “Interestingly, the frequency of de novo, or new, CNVs identified in these patients with cerebral palsy is even more significant than some of the major CNV autism research from the last 10 years. We’ve opened many doors for new research into cerebral palsy.”
“Finding an underlying cause for a child’s disability is an important undertaking in management,” says Dr. Michael Shevell, co-director of the Canadian Cerebral Palsy Registry and Chair of the Department of Paediatrics at the MCH-MUHC. “Parents want to know why their child has particular challenges. Finding a precise reason opens up multiple vistas related to understanding, specific treatment, prevention and rehabilitation. This study will provide the impetus to make genetic testing a standard part of the comprehensive assessment of the child with cerebral palsy.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019